Navigation Links
Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
Date:8/24/2009

HOERSHOLM, Denmark, August 24 /PRNewswire/ --

- Santaris Pharma A/S and Shire plc to Engage in a Multi-Year Research Program Utilizing Santaris Pharma's Proprietary Locked Nucleic Acid (LNA) Drug Platform to Identify and Select Drug Candidates Against Certain Targets for the Treatment of Rare Genetic Disorders

- Santaris Pharma A/S to Receive Significant Upfront Payments, Milestone Payments and Royalties for Providing Access to its LNA Technology, Exclusivity for Three Pre-Defined Targets and Funding for Discovery

- Partnership for the Treatment of Rare Genetic Disorders Further Demonstrates Versatility of the LNA Drug Platform to Develop RNA-Based Medicines for a Range of Disease Areas Including Metabolic Disorders, Cancer, Infectious and Inflammatory Diseases

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic disorders.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

The alliance will use Santaris Pharma A/S' proprietary Locked Nucleic Acid (LNA) Drug Platform to identify and select drug candidates against certain targets. Shire will be responsible for the selection of appropriate drug candidates, as well as further development and commercialization of products arising from the alliance.

Under the terms of the agreement Santaris Pharma A/S will receive initial early stage payments of US$6.5 million covering technology access, exclusivity for three pre-defined targets and initial discovery funding, and an additional early stage payment of US$13.5 million upon successful completio
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
2. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
3. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
4. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
5. Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board
6. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
7. Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 Auction
8. Pre-Owned Prices on Premium Pharmaceutical Equipment
9. Laureate Pharma Elects New Board Member
10. CBI Hosts 5th Annual Pharma/Biotech Enterprise Governance, Risk and Controls Congress
11. PharmaTelevision Launches the First Daily News Show for the Life Sciences Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Yuma Regional Cancer ... complementary therapies brings comprehensive cancer care to Yuma, ... Regional Cancer Center has officially opened. A Mayo ... includes services such as open, semi-private and private ... Cancer Society Resource Center, hematology, rehabilitation center, a ...
(Date:7/30/2014)... 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), ... proprietary technologies are used to discover, develop, manufacture ... bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... as Vice President and Chief Financial Officer. Tom ... information technology operations for Dyadic and will succeed ...
(Date:7/30/2014)... DIEGO , July 30, 2014   Epic ... designs and develops novel diagnostics to personalize and advance ... appoint of Gregory T. Lucier as chairman ... chairman and CEO of Life Technologies (formerly Invitrogen). Mr. ... as Epic commercializes its circulating rare cell analysis platform ...
(Date:7/30/2014)... , July 30, 2014  RXi ... a biotechnology company focused on discovering, developing ... medical needs using RNA-targeted technologies, today announced ... with RXI-109, for the reduction of recurrence ... surgery, has been initiated. Logo ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... anthrax that is more effective and easier to administer than ... mice and guinea pigs, report University of Michigan Medical School ... , The scientists were able to trigger a strong immune ... a nanoemulsion a suspension of water, soybean oil, alcohol ...
... engineers assemble spacecraft, have joined hot springs, ice ... scientists have discovered ultra-hardy organisms collectively known as ... recent NASA study have never been detected anywhere ... led the study conducted at NASAs Jet Propulsion ...
... method for culturing mammalian neurons in chambers not much larger ... of the neurons at very low densities, an essential step ... of individual brain cells. , The technique is described this ... Lab on a Chip. , This finding will be ...
Cached Biology Technology:Anthrax vaccine produces immunity with nanoparticles, not needles 2Anthrax vaccine produces immunity with nanoparticles, not needles 3NASA study will help stop stowaways to Mars 2Microfluidic chambers advance the science of growing neurons 2Microfluidic chambers advance the science of growing neurons 3
(Date:7/30/2014)... University Press (OUP) is pleased to announce its new ... in 2015, OUP and CINP will partner to publish ... as a fully open-access journal. , Alan Frazer, Editor-in-Chief ... the size and expertise of OUP will further facilitate ... one of the very leading journals within neuropsychopharmacology. The ...
(Date:7/30/2014)... York , July 30, 2014 ... on Global Government Biometric Systems Market 2014-2024 ... The Global Biometric Systems Market 2014-2024" offers ... systems market over the next ten years, alongside ... detailed market size forecasts. To view ...
(Date:7/30/2014)... help Americans make better decisions about what they eat, ... proposed significant changes to the Nutrition Facts label found ... article in Chemical & Engineering News (C&EN), ... explains the suggested updates and the fight that ... C&EN, points out that while the Nutrition Facts label ...
Breaking Biology News(10 mins):OUP to partner with the International College of Neuropsychopharmacology 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10
... bird in hand is worth two in the bush may ... the lab of ASU School of Life Sciences Professor Roy ... at the Biodesign Institute. There, associate research scientist ... targets to develop a vaccine against a leading poultry disease, ...
... working gene is inserted into a cell to replace a ... the prevention and treatment of disease. Now a ... a counterintuitive approach also holds promise. The targeted removal of ... would do -- can restore cellular function in cells with ...
... United Kingdom and France have identified four separate ... Creutzfeldt-Jakob disease. The study, published March 14th in ... subgroups could represent distinct prion strains in what ... Prion diseases are transmissible neurodegenerative disorders characterized by ...
Cached Biology News:Solving an avian scourge could also provide benefits to human health 2Solving an avian scourge could also provide benefits to human health 3Work with power grids leads to cell biology discovery 2Work with power grids leads to cell biology discovery 3
... software, PC, is used to perform ... obtained from the Experion automated electrophoresis ... electropherogram and simulated gel views and ... in a Results table. This software ...
... to PRKAR2 cAMP is a signaling ... functions. cAMP exerts its effects by activating ... the signal through phosphorylation of different target ... a tetramer composed of two regulatory and ...
The large Dodeca stainer shaking rack holds the staining trays in the large Dodeca stainer....
...
Biology Products: